NCT06110793: An ongoing trial by Memorial Sloan Kettering Cancer Center
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06110793 |
|---|---|
| Title | A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 29, 2023 |
| Completion date | Nov. 30, 2026 |
| Required reporting date | Nov. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |